Mild Cognitive Impairment as a Target for Drug Development
Mild Cognitive Impairment as a Target for Drug Development. Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School of Medicine. Aging, AAMI (ARCD), MCI, and AD. 1 SD. Elderly. Young. Frequency. A. B. AD. MCI. AAMI. Cognitive Performance.
836 views • 20 slides